Riparian forest (CP22) buffers are implemented in the Chesapeake Bay Watershed to trap pollutants in surface runoff thus minimizing the amount of pollutants entering the stream network. For these buffers to function effectively, overland flow must enter the riparian zones as dispersed sheet flow to facilitate slowing, filtering, and infiltrating of surface runoff. The occurrence of concentrated flowpaths, however, is prevalent across the watershed. Concentrated flowpaths limit buffer filtration capacity by channeling overland flow through or around buffers. In this study, two topographic metrics (topographic openness and flow accumulation) were used to evaluate the occurrence of concentrated flowpaths and to derive effective CP22 contributing areas in four Long-Term Agroecosystem Research (LTAR) watersheds within the Chesapeake Bay Watershed. The study watersheds include the Tuckahoe Creek watershed (TCW) located in Maryland, and the Spring Creek (SCW), Conewago Creek (CCW) and Mahantango Creek (MCW) watersheds located in Pennsylvania. Topographic openness identified detailed topographic variation and critical source areas in the lower relief areas while flow accumulation was better at identifying concentrated flowpaths in higher relief areas. Results also indicated that concentrated flowpaths are prevalent across all four watersheds, reducing CP22 effective contributing areas by 78% in the TCW, 54% in the SCW, 38% in the CCW and 22% in the MCW. Thus, to improve surface water quality within the Chesapeake Bay Watershed, the implementation of riparian forest buffers should be done in such a way as to mitigate the effects of concentrated flowpaths that continue to short-circuit these buffers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.